Compare Manhattan Associates Inc (MANH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Manhattan Associates Inc trades at $204.05 (market cap $12.06B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Manhattan Associates Inc is more actively traded (376,150 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MANH | XBI | |
|---|---|---|
Market Cap | $12.06B | $10.11B |
Volume | 376,150 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $223.76 | $169.55 |
52-Week Low | $120.88 | $104.99 |
Typical Hold Time | 12 Days | 38 Days |
Enterprise Value | $11.93B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $205.29, up 1.57% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 18.67% net margins and consistent earnings beats, though valuation metrics remain elevated. Recent news includes product expansion with Editions launch and ongoing legal investigations regarding fiduciary duties.
Outlook remains positive with analyst consensus at Buy and $210.50 target, though risks include high valuation multiples and legal scrutiny. The stock offers growth potential through strong operational performance but faces headwinds from potential governance concerns and competitive pressures in the software sector.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
